We take an active role in our portfolio companies, contributing expertise in drug discovery, development and operations.
StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.
We aim to work with our portfolio companies to help them deliver maximum patient value by contributing both capital and expertise.
28 March 2019. StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseasesread more
19 February 2019. CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreementread more
03 January 2019. StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officerread more
Selected Invested Funds
Arix Bioscience supports medical innovation at all stages of development and has access to breakthrough academic science.
Pappas is dedicated to furthering life science discoveries and delivering groundbreaking solutions to market.
Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development.